Early treatment with intravenous β-blockers for acute coronary syndromes
Review presents results of studies, which have demonstrated both efficacy and unsafeness of early β-blocker treatment in acute coronary syndromes (ACS). Indications and contraindications for administration of intravenous β-blockers to patients with ACS are considered. Only a clinical approach based on careful weighing of benefits and risks is a single reasonable approach to making a decision on expediency of using early (intravenous) β-blockers. In ACS cases either with or without ST elevation, intravenous β-blocker formulations allow earlier and safer initiation of β-blocker treatment.